XML 44 R29.htm IDEA: XBRL DOCUMENT v3.25.4
Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Significant Accounting Policies [Abstract]  
Schedule of Revenues

The Company’s revenue consists of (in thousands):

 

   Year Ended December 31, 
   2025   2024   2023 
Services  $368   $346   $353 
Products   314    27    5 
Total  $682   $373   $358 
Schedule of Net Sales Based on Disaggregation Criteria

Total net sales based on the disaggregation criteria described above are as follows (in thousands):

 

   Year Ended December 31, 
   2025   2024   2023 
   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total   Point-in-Time   Over Time   Total 
Americas  $21   $571   $592   $27   $346   $373   $5   $337   $342 
Europe   53    12    65    
-
    
-
    
-
    
-
    16    16 
Asia           23    2    25    
         -
    
-
    
-
    
      -
    
-
    
-
 
Total  $97   $585   $682   $27   $346   $373   $5   $353   $358 
Schedule of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share (in thousands, except for per share data):

 

   Year Ended December 31, 
   2025   2024   2023 
Basic net income (loss) per common share:            
Numerator:            
Net loss  $(18,674)  $(68,542)  $(27,022)
Less: Series A convertible preferred stock dividends   
-
    
-
    861 
Net loss available to common stockholders   (18,674)   (68,542)   (27,883)
                
Denominator:               
Weighted average outstanding shares of common share - basic   164,492    93,881    66,611 
Loss per common share – basic and diluted  $(0.11)  $(0.73)  $(0.42)
Schedule of Computation of Diluted Net Loss Per Common Share, as Their Effect Would be Anti-Dilutive The following is a summary of the weighted average common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive (in thousands):
   Year Ended December 31, 
   2025   2024   2023 
Warrants   1,599    2,583    6,053 
Options   5,510    12,907    12,280 
Unvested restricted common stock   1,200    2,997    1,192 
Total potentially dilutive shares   8,309    18,487    19,525